drugset / Trial / NCT00378014
Preservation of Renal Function in Liver Transplant Recipients With Certican Therapy
RandomizedParallel-groupOpen-labelTreatment
Summary
The study is designed to show that everolimus initiation together with reduction and thereafter discontinuation of calcineurin inhibitor (CNI) will improve significantly renal function in de novo liver transplant recipients as compared to continuation of CNI-based treatment.
Timeline
- Start
- 2006-08
- Primary completion
- 2013-01
- Completion
- 2013-01
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Comparator | Everolimus | Small molecule | 1.5 mg | — |
| Background | Basiliximab | Monoclonal antibody | — | — |
Indications
No indication recorded.